Walleye Trading’s Lexicon Pharmaceuticals LXRX Stock Holding History

Walleye Trading’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-50,000	Closed	-$230K	–	5499
2021 Q2	$230K	Buy	+50,000	New	+$241K	﹤0.01%	3785

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Walleye Trading's LXRX Position: Q3 2016 in Review

Walleye Trading sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2016, closing a stake of 2,100 shares — an estimated $30K sold.

Walleye Trading first reported a position in LXRX in Q4 2015 and held it in 3 quarters. The position peaked at $71K in Q1 2016. 144 funds tracked by Wall St. Rank hold LXRX as of Q3 2016.

Walleye Trading reported no remaining Lexicon Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Walleye Trading sold 2,100 Lexicon Pharmaceuticals shares in Q3 2016, an estimated $30K.
Walleye Trading first reported a position in Lexicon Pharmaceuticals in Q4 2015 and held it in 3 quarters.
Walleye Trading's Lexicon Pharmaceuticals position peaked at $71K in Q1 2016.
144 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2016.

Based on Walleye Trading's 13F filing for Q3 2016, filed 14 Nov 2016.